Rntcp full details
Reading Document
Medical Text Search
RNTCP Revised National Tuberculosis Control Programme India history objectives structure
Medical Text Search
RNTCP DOTS strategy TB diagnosis treatment regimen categories
GradeResponse
GradeResponse
The retrieval returned limited results. I'll now synthesize a full answer from my knowledge, supplemented by what was retrieved.
RNTCP – Revised National Tuberculosis Control Programme
1. Overview
The Revised National Tuberculosis Control Programme (RNTCP) was India's national program for TB control, launched in 1997 and scaled up across the entire country by 2006. It was built on the WHO-recommended DOTS (Directly Observed Treatment, Short-course) strategy. In 2020, RNTCP was rebranded and expanded into the National Tuberculosis Elimination Programme (NTEP), aligned with India's goal to eliminate TB by 2025 (five years ahead of the global 2030 SDG target).
2. Historical Background
| Year | Milestone |
|---|---|
| 1962 | National TB Programme (NTP) launched — largely ineffective due to poor supervision and irregular drug supply |
| 1992 | NTP evaluated; failure due to lack of DOTS, no sputum microscopy focus, lengthy regimens |
| 1993 | Pilot DOTS projects launched in select districts |
| 1997 | RNTCP formally launched (Phase I) |
| 1998–2006 | Phased scale-up across all districts |
| 2006 | Nationwide coverage achieved |
| 2012 | RNTCP revised — new drug regimens, Category-IV for MDR-TB |
| 2020 | Renamed NTEP with expanded scope |
3. Objectives of RNTCP
- Detection of at least 70% of new sputum smear-positive TB cases
- Treatment success rate of at least 85% in detected cases
- Reduce prevalence and mortality due to TB
- Prevent emergence of drug-resistant TB
- Reduce socioeconomic burden of TB on patients and families
4. DOTS Strategy – The Core of RNTCP
According to Harrison's Principles of Internal Medicine (p. 5197), the essential elements include:
- Early case detection + bacteriologic confirmation (sputum smear microscopy)
- Standardized short-course chemotherapy with direct supervision
- Uninterrupted drug supply of proven quality
- Monitoring and evaluation system with defined treatment outcomes
- Government commitment with adequate funding and logistics
5. Organisational Structure
Central Level
└── Central TB Division (CTD), Ministry of Health & Family Welfare
State Level
└── State TB Cell (STC) — State TB Officer (STO)
District Level
└── District TB Centre (DTC) — District TB Officer (DTO)
Sub-District Level
└── TB Unit (TU) — Medical Officer-TC (MO-TC)
[1 TU per 500,000 population; 1 per 250,000 in tribal/hilly areas]
Peripheral Level
└── Designated Microscopy Centres (DMCs)
[1 DMC per 100,000 population]
6. Case Definitions
By Bacteriology
| Type | Definition |
|---|---|
| Smear-positive | ≥2 sputum smears AFB+, OR 1 smear + culture positive, OR 1 smear + radiographic evidence |
| Smear-negative | ≥3 smear-negative specimens + radiographic evidence + no response to antibiotics |
| Extra-pulmonary TB (EPTB) | TB in organs other than lungs |
By Treatment History
| Category | Definition |
|---|---|
| New | Never treated or treated for <1 month |
| Relapse | Previously cured/treatment-completed, now smear-positive again |
| Failure | Smear-positive at 5 months or later during treatment |
| Treatment after default | Returned after ≥2 months interruption |
| Others | Chronic or previously treated, smear-positive |
7. Diagnostic Approach
Pulmonary TB
- Sputum smear microscopy (ZN stain) – 2 specimens (spot + morning)
- Chest X-ray – supportive
- Culture (LJ medium or MGIT) – gold standard
- CBNAAT (Cartridge-Based Nucleic Acid Amplification Test) / GeneXpert – rapid diagnosis + RIF resistance detection (introduced under RNTCP in 2012–13)
- Line Probe Assay (LPA) – for MDR-TB detection
Extra-pulmonary TB
- Biopsy, CSF analysis, FNAC, pleural fluid analysis + adenosine deaminase (ADA)
8. Treatment Regimens
RNTCP used two treatment categories (later revised):
Category I (New Cases)
Indicated for: New smear-positive, smear-negative with severe disease, severe EPTB
| Phase | Duration | Drugs | Frequency |
|---|---|---|---|
| Intensive Phase (IP) | 2 months | HRZE (Isoniazid + Rifampicin + Pyrazinamide + Ethambutol) | Thrice weekly (DOT) |
| Continuation Phase (CP) | 4 months | HRE | Thrice weekly (DOT) |
Regimen: 2(HRZE)₃ / 4(HRE)₃
Category II (Previously Treated)
Indicated for: Retreatment cases (relapse, failure, default)
| Phase | Duration | Drugs |
|---|---|---|
| IP | 2 months | HRZES (+ Streptomycin in month 1) |
| Extended IP | 1 month | HRZE |
| CP | 5 months | HRE |
Regimen: 2(HRZES)₃ / 1(HRZE)₃ / 5(HRE)₃
Note: After 2012 revisions, Category III was abolished and merged into Category I. Category IV was established for MDR-TB.
Category IV (MDR-TB)
- Kanamycin / Amikacin + Fluoroquinolone + Ethionamide + Cycloserine + PAS
- Duration: 24–27 months
- Managed at DOTS-Plus sites
9. Drug Dosing (Weight-Based Bands)
RNTCP used fixed-dose combination (FDC) tablets with weight-band dosing:
| Weight Band | No. of FDC Tablets |
|---|---|
| 25–39 kg | 2 tablets |
| 40–54 kg | 3 tablets |
| 55–69 kg | 4 tablets |
| ≥70 kg | 5 tablets |
10. DOTS – Directly Observed Treatment
- A trained health worker observes every dose being swallowed
- DOT providers: ASHA workers, anganwadi workers, self-help group members, NGOs, private practitioners
- Thrice-weekly (intermittent) dosing under original RNTCP
- Shifted to daily dosing under NTEP (2019 guidelines)
11. Treatment Outcomes (WHO-defined)
| Outcome | Definition |
|---|---|
| Cured | Smear-negative at end of treatment + at least once during treatment |
| Treatment completed | Completed treatment without smear confirmation |
| Died | Died during treatment for any reason |
| Treatment failure | Smear-positive at ≥5 months |
| Defaulted | Treatment interrupted ≥2 consecutive months |
| Transferred out | Outcome unknown |
12. Recording and Reporting
| Register/Form | Purpose |
|---|---|
| TB Register | Master register at TU level |
| Laboratory Register | At DMC for microscopy results |
| Treatment Card | Individual patient card |
| Referral/Transfer forms | Patient transfer between TUs |
| Quarterly reports | Case detection + treatment outcomes |
Nikshay Portal – India's web-based TB case notification and management system (mandatory notification from 2012 for government + private sector).
13. Special Situations
TB-HIV
- All TB patients tested for HIV (Provider-Initiated Testing and Counseling – PITC)
- ART started within 2 weeks of TB treatment regardless of CD4 count
- Cotrimoxazole prophylaxis
Pediatric TB
- Diagnosis based on: symptoms, contact history, Mantoux test, CXR, FNAC
- Dosing adjusted by weight bands
- No sputum-based diagnosis for most children
TB in Pregnancy
- Standard Cat I regimen (HRZ + E) is safe
- Avoid Streptomycin (ototoxic to fetus)
Drug-Resistant TB (DR-TB)
- MDR-TB: Resistant to Isoniazid + Rifampicin
- XDR-TB: MDR + resistance to any fluoroquinolone + any injectable second-line drug
- Managed under PMDT (Programmatic Management of Drug-resistant TB)
14. Transition to NTEP (2020)
RNTCP evolved into NTEP with key changes:
| Feature | RNTCP | NTEP |
|---|---|---|
| Treatment frequency | Thrice weekly | Daily dosing |
| Drug regimen | Cat I/II | Universal DST-based |
| Diagnosis | Smear + CBNAAT | Universal CBNAAT/molecular testing |
| MDR-TB | Injectables-based | All-oral regimens (BPaL) |
| Notification | Mandatory (2012) | Strengthened, digital (Nikshay) |
| Goal | Reduce burden | Eliminate TB by 2025 |
15. Key Indicators
| Indicator | RNTCP Target |
|---|---|
| Case detection rate | ≥70% |
| Treatment success rate | ≥85% |
| Sputum conversion rate (2 months) | ≥80% |
| Default rate | <10% |
16. Funding and Partnerships
- Funded by Government of India with support from World Bank, USAID, GFATM (Global Fund)
- Technical support: WHO, CDC, FIND, The Union
- NGO and private sector engagement through PPM (Public-Private Mix)
Summary
RNTCP was a landmark public health programme that brought India's TB control efforts in line with international DOTS standards. It dramatically improved case detection and treatment success rates, saving millions of lives. Its successor NTEP continues this mission with more advanced diagnostics, all-oral MDR-TB regimens, daily dosing, and a bold 2025 elimination target.
This is a shared conversation. Sign in to Orris to start your own chat.